July 4, 2020 : Issue #1049 TOP STORIES - Diabetes News & Research |
|
Letter from the Editor
 Do you have a lot of your patients telling you about their success with Keto diets? It seems that for years we were concerned about these diabetes patients going into ketoacidosis if they tried a low carb, higher fat diet. Professionally, we know there is a difference between ketosis and ketoacidosis, and now it is important to make that distinction for our patients.
In the past weight loss and lower A1c values were thought to be the only benefits of a low carb, ketosis diet. However, this week our intern Maya Palmer, PharmD candidate from FAMU College of Pharmacy, has found excellent evidence that these types of diets can actually cause long term remission in type 2 diabetes. Check out her article to learn how often these patients become medication free.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
|
Doctor's Option lab test products include rapid tests and CLIA certified fingerstick lab tests.
Rapid tests offer immediate test results to provide doctors with point of care test results in as little as 90 seconds.
Fingerstick lab tests provide CLIA certified lab accurate results. Each fingerstick lab test collection kit comes with a prepaid postage return envelope and everything you need to obtain and collect your fingerstick blood sample in a 510K FDA approved device.
Fingerstick lab tests are great for people who want to monitor their blood sugar, cholesterol, lipids and other important bio-markers at home or on the go.
Visit Doctor's Option |
|
|
|
|
 Newsflash: Gvoke HypoPen™ Now Available
Gvoke HypoPen is the first FDA approved glucogon autoinjector for very low blood sugar. It is premixed and ready-to-go, with no visible needle. |
TOP STORIES - Diabetes News and Research |
|
| Exercising with Type 1 Diabetes: The Insulin-Food Balance Challenge
by Sheri Colberg, Ph.D., FACSM
Addressing how to balance blood glucose levels during (and after) exercise with type 1 diabetes is not new. In fact, it is likely the KEY topic to address to be successful at being physically active if you take exogenous insulin and want to prevent hypoglycemia or hyperglycemia during exercise. |
| |
|
|
|
|
| Did You Know? Metformin May Lower Mortality Risk for COVID-19
Once again, metformin has shown the ability to be a wonder drug. Studies have shown that type 2 diabetes (T2DM) and obesity are significant risks for mortality in COVID-19. Now, according to a new study published by MedRxiv, women who were taking metformin had a 21% to 24% lower risk of dying from COVID-19, compared to men and those who didn't take the drug, based on data from 6,200 hospitalized COVID-19 patients. The study also found that metformin lowered C-reactive protein levels twice as much in women as in men. Metformin has sex specific immunomodulatory effects which may elucidate treatment mechanisms in COVID-19.
“We know that metformin has different effects on men and women,” study coauthor Carolyn Bramante of the University of Minnesota said, adding that "In the diabetes prevention trial, metformin reduced CRP (the inflammation marker C-reactive protein) twice as much in women as men." Metformin also decreases levels of TNF-alpha, an inflammation protein that appears to make COVID-19 worse, she said. "The fact that we saw the benefit in women only, and the fact that metformin lowers TNF-alpha in female mice, might suggest that the TNF-alpha effects of metformin are why it helps in COVID-19."
This small study has not yet been peer-reviewed. MedRxiv See more of our coverage of metformin & COVID-19. |
|
|
| Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters: Stephanie Anderson, PharmD Candidate 2021, Skaggs School of Pharmacy and Pharmaceutical Sciences Sameen Khan, Pharm.D. Candidate, USF College of Pharmacy Maya Palmer, PharmD. Candidate, Florida A&M University College of Pharmacy Stephen Rubano, PharmD. Candidate, USF Taneja College of Pharmacy |
|
|
|
|
|
|  About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control. |
| Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com |
|
|
|
|
| ©2020 HIPER, LLC. All rights reserved.
This email was sent by eHealthcare Solutions on behalf of: |
|
|
|
|
|
|
